Amer Zeidan, MBBS

Amer Zeidan, MBBS, is director of Early Therapeutics Research, director of the Leukemia and Myeloid Malignancies Program, assistant medical director of the Clinical Trials Office, and co-leader of the Leukemia and Myeloid Malignancies Clinical Research Team at Yale Cancer Center; as well as chief of the Division of Hematologic Malignancies and a professor of internal medicine (hematology) at Yale School of Medicine

Articles

An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients

June 19th 2025

Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Dr Zeidan on the Evaluation of Immunotherapy and Other Novel Therapies in MDS

May 8th 2025

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

The Potential of Oral HMAs in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Other Potential Roles for Luspatercept in MDS And Beyond

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

The Importance of Treating Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Dissecting the Current Treatment Landscape in MDS

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Dr Zeidan on Classification and Treatment Updates in MDS

December 1st 2023

Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.

Dr Zeidan on Imetelstat in Lower-Risk MDS

June 2nd 2023

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.

x